New Developments in the Courts and Congress Influencing IP Due Diligence

November 15, 2019 8:15am

Tom Irving
Finnegan, Henderson, Farabow, Garret & Dunner, LLP (Washington, DC)

Hilary J. Libka
Intellectual Property Counsel
Dana-Farber Cancer Institute, Inc. (Boston, MA)

Jane M. Love
Gibson Dunn (New York, NY)

Henry H. Gu
Vice President, Chief IP Counsel
Akebia Therapeutics, Inc. (Cambridge, MA)


Ryan Murphey
Ropes & Gray LLP (New York, NY)

This session will provide you with insights into how recent court decisions, and pending legislation relating to patent rights will impact life sciences pipelines and reshape future business analyses. Points of discussion during this session will include:
  • Factoring recent developments in life sciences IP case law
  • Reviewing pending patent reform legislation and adapting the due diligence analysis
  • Understanding the USPTO’s guidance on §101 and related considerations in patent applications